Bone marrow stem cells for chronic graft-versus-host disease
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests whether giving bone marrow stem cells (called MesenCell) by IV can help people with chronic graft-versus-host disease (GVHD) — a condition where donor cells attack the body after a transplant. It may offer a new option when standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Have had a stem cell transplant from a donor (allogeneic)
- Have moderate or severe chronic graft-versus-host disease (GVHD) that has not improved with standard medicines
- Be willing to participate and sign a consent form
- Not be pregnant or have a current cancer recurrence
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.